
Professor and Director, SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE
Member of the Healthcare Council
Bernard Chaitman, MD, is Professor of Internal Medicine and Director of Cardiovascular Research at the St. Louis University School of Medicine in Missouri. He is also the Director of the Core ECG Laboratory. Dr. Chaitman has research interests in anti-anginal drug therapies, including Ranolazine, Nicorandil, fasudil, and ivabradine; lipid lowering therapies, including investigational LDL lowering and HDL elevating therapy; ECG and QT analysis for drug registration studies; cardiac event classification for large cardiovascular multi-center clinical trials; non-invasive stress testing and cardiac risk stratification; indications for coronary revascularization; NSAID risk in cardiac patients; exercise physiology and training; nutrition; coronary artery disease; and noninvasive cardiac risk stratification. He is one of the Principal Investigators in the world's largest clinical trial comparing coronary revascularization to medical therapy in diabetic subjects. Dr. Chaitman is Board-certified in Internal Medicine, Cardiovascular Diseases, and Echocardiography. He is a Fellow of the American College of Cardiology and the American Heart Association Council on Clinical Cardiology and has served as President of the St. Louis Greater Division of the American Heart Association from 1998 to 2000. Dr. Chaitman has also served as chair for numerous Data and Safety Monitoring Boards and Cardiac Event Adjudication Committees for NIH and industry sponsored clinical trials. (This is me - Update Profile)
Bernard Chaitman has not published any GLG News Analyses.
| Study Group Name | No. Members |
|---|---|
| General Cardiologists (US) | 1324 |
| Heart Failure Specialists (US) | 981 |
| Non-Electrophysiologist Cardiologists (US) | 852 |
| Physicians who Treat Hypertension (US) | 816 |
| Physicians who Treat Arrhythmia (US) | 307 |
Bernard Chaitman has not participated in any GLG Live Meetings.